AJP - Regulatory, Integrative and Comparative Physiology, Vol 265, Issue 3 524-R529, Copyright © 1993 by American Physiological Society

ARTICLES

Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate

J. Luk, I. Ajaelo, V. Wong, J. Wong, D. Chang, L. Chou and I. A. Reid
Department of Physiology, University of California, San Francisco 94143-0444.

Arginine vasopressin (AVP) elicits a larger decrease in heart rate for a given increase in arterial pressure than do other vasoconstrictors, but there is disagreement as to whether this results from an increase in baroreflex gain or a resetting of the baroreflex to a lower blood pressure. It is also unclear which type of vasopressin receptor mediates the action of vasopressin on the baroreflex. In the present study, the effects of vasopressin, selective vasopressin V1 and V2 receptor agonists, oxytocin, and a vasopressin V1 receptor antagonist on the baroreflex control of heart rate were investigated in conscious, chronically prepared rabbits. Baroreflex curves were generated with intravenous infusions of phenylephrine and nitroprusside and analyzed using a four-parameter logistic model. Intravenous infusion of vasopressin at 5 ng.kg-1.min-1 increased mean arterial pressure by 9 mmHg and decreased heart rate by 31 beats/min. The arterial pressure at the midrange of the baroreflex curve (BP50) decreased from 75.9 +/- 4.8 to 57.6 +/- 1.7 mmHg (P < 0.01), indicating a shift of the baroreflex curve to a lower pressure, but the gain did not change significantly. The actions of vasopressin on blood pressure, heart rate, and BP50 were completely blocked by pretreatment with d(CH2)5[Tyr(Me)2]AVP, a selective V1 receptor antagonist. Infusion of [Phe2,Ile3,Orn8]AVP, a selective V1 receptor agonist, produced cardiovascular effects similar to those of vasopressin and decreased the BP50 of the baroreflex from 73.0 +/- 2.2 to 63.8 +/- 2.2 mmHg (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				E. G. Krause, K. S. Curtis, J. P. Markle, and R. J. Contreras Oestrogen affects the cardiovascular and central responses to isoproterenol of female rats J. Physiol., July 1, 2007; 582(1): 435 - 447. [Abstract] [Full Text] [PDF]

				J. A. Guzman, A. E. Rosado, and J. A. Kruse Vasopressin vs. norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects J Appl Physiol, August 1, 2003; 95(2): 803 - 809. [Abstract] [Full Text] [PDF]

				C. L. Holmes, B. M. Patel, J. A. Russell, and K. R. Walley Physiology of Vasopressin Relevant to Management of Septic Shock Chest, September 1, 2001; 120(3): 989 - 1002. [Abstract] [Full Text] [PDF]

				W. Huang, M. Sjoquist, O. Skott, E. M. Stricker, and A. F. Sved Oxytocin antagonist disrupts hypotension-evoked renin secretion and other responses in conscious rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2001; 280(3): R760 - R765. [Abstract] [Full Text] [PDF]

				D. B. Sampey, L. M. Burrell, and R. E. Widdop Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1999; 276(3): R872 - R879. [Abstract] [Full Text] [PDF]

				Y. Nishida, H. Hosomi, and V. S. Bishop Long-term effects of AVP-induced neurohumoral interaction via area postrema on body fluid and blood pressure Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1997; 273(5): R1696 - R1703. [Abstract] [Full Text] [PDF]

				I. A. Reid Role of Vasopressin Deficiency in the Vasodilation of Septic Shock Circulation, March 4, 1997; 95(5): 1108 - 1110. [Full Text]